|
|
Countries covered: Global
With end users of prescription drugs seeking to pay less for medication, generic and biogeneric products are poised for strong growth, especially in the developing nations. However, this may not be the case in developed regions - especially in the United States and Europe - where market growth is likely to be restricted due to concerns over patent infringements and lack of clear-cut regulatory processes for approval of generic and biogeneric drugs. Currently, regulations pertaining to introduction of generics apply only to small molecule drugs while the regulatory process for large molecule, protein-based biotech products is yet to be defined. Even a minor change in the manufacturing process is likely to trigger major changes in biological activity that are distinctly different from original products and this mandates the use of clinical testing of biogeneric drugs prior to their approval. Frost & Sullivan’s recent study analyzes the worldwide market for generic and biogeneric products. It focuses on the United States, European, Asian, and the Rest-of-the-World (ROW) markets. The research provides a comprehensive snapshot of the competitive landscape, revenue and prescription forecasts, technology trends, and challenges. Weak Patent Laws Aid Market Growth of Generic Drugs in Developing Nations Generic drug manufacturers in developing nations, aided by weak patent laws, are focusing on producing blockbuster drugs that are still under patent protection. "In India, for example, drug manufacturers may patent a process but not a compound, thus, generic drug makers are able to synthesize the compound through another process and may legally introduce another version of the drug," explains the research analyst of this study. "In this manner, they can benefit from the original manufacturer’s ongoing advertising and promotion of the drug while eliminating the need to depend on the American and European generics producers." In an endeavor to avoid the stringent patent processes, generic manufacturers may lose some quality in the process of reengineering drugs. Several Asian and ROW generics producers have faced similar difficulties and one recent example is the removal of two generic HIV drugs produced by a prominent Indian pharmaceutical company from the WHO list of approved medications meant specifically for patients in Africa. Consumer Belief in Branded Products Restricts Use of Generics Though generics and biogeneric drugs are emerging as strong contenders to branded medications, a number of consumers in developed nations have a perception that branded products are more effective than unbranded ones. "Certain patient populations tend to view healthcare benefits as entitlements rather than privileges and resist shifting from more expensive to less expensive options," says the analyst. Even when they are compelled to switch drugs, they shift from one brand to another - popularly known as a ‘brand name shift’ - despite the availability of low-cost generics. This is one challenge that generic drug manufacturers are likely to find hard to overcome in their quest to extend market reach. |
More Global Genetic Engineering Reports
Genetic Engineering by
Global Industry Analysts
The global outlook series on Genetic Engineering provides a collection of market briefs and concise summaries of research findings. The report offers an aerial view ...
The 2009-2014 World Outlook for Gene Expression Services by
Icon Group International, Inc.
This econometric study covers the world outlook for gene expression services across more than 200 countries. For each year reported, estimates are given for the ...
Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development by
Kalorama Information
With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new ...
Biogenerics by
Global Industry Analysts
This report analyzes the worldwide markets for Biogenerics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. ...
Medical and Biological Sensors and Sensor Systems: Markets, Applications, and Competitors Worldwide by
Kalorama Information
The commercial world of medical sensors is vibrant and evolving rapidly.
Reports that are only a year or two old are already out-of-date as new
...
See all reports like this >>
Related Markets
Genetic Engineering Reports
- Genetic Engineering
- Stem Cell Markets
- Patent map and technology intelligence report. Micro-organisms/Enzymes; Propagating, Preserving Or Maintaining Micro-organisms; Genetic Engineering; Culture Media
- The World Market for Biosimilars and the Potential for US Follow-on Biologics
- Stem Cell Technology: Current Applications and Future Directions